NTI is a specialty biopharmaceutical company with expertise in identifying and acquiring promising drug candidates and in designing and managing late- stage clinical trials for central nervous system conditions. The Company is currently developing Viprinex (ancrod), a novel reperfusion agent that is in pivotal Phase 3 trials for the treatment of acute ischemic stroke.

Contact Information

2000 Powell Street
Suite 800
Emeryville, CA 94608

tel: 510-595-6000
fax: 510-595-6006


Investor Relations



Exchange: NASDAQ
Industry: Biotechnology
Market Cap: $56.7M

The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.